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Introduction
Melanoma is considered to be one of the best examples of 
an immunogenic tumor. Different observations have led to this 
assumption: (1) primary melanomas often exhibit strong lympho-
cytic infiltration, that could induce partial or complete regression, 
(2) development of vitiligo is a marker of better prognosis in mel-
anoma patients,1 and (3) immunotherapies have shown remark-
able long-term results.2,3 The observation that immune response 
affects tumors biology dates back to the late 1800s, when Wil-
liam B Cooley observed remission of lesions in patients injected 
with a mixture of dead Streptococcus pyogenes and dead Serratia 
marcescens bacteria. Current approaches to cancer immunother-
apy include: (1) non-specific stimulation of antitumor immune 
response by stimulating endogenous effector cells with cytokines, 
(2) active immunization, (3) adoptive immunotherapy, and (4) 
targeting of immune checkpoints or immune regulatory mole-
cules (Fig. 1). Currently approved melanoma therapeutics by the 
US Food and Drug Administration (FDA) for the treatment of 
melanoma, are listed in Figure 2. The aim of this review is to 
summarize different types of immunotherapy agents, as well as to 
discuss different treatment strategies, complementary regimens, 
and possible biomarkers of response to the treatment.
Cytokines
Interleukin-2 (IL-2)
The first type of immunotherapy approved in the treatment 
of melanoma was high-dose interleukin 2 (HD IL-2), which 
provided a “proof-of-principle” for the use of immunotherapy in 
melanoma.2 Interleukin-2 plays a central role in the activation 
and stimulation of T lymphocytes and natural killer (NK) cells. 
In response to IL-2 stimulation these cells acquire cytolytic prop-
erties which is believed to enhance their anti-tumoral properties.4
IL-2 in advanced melanoma
HD IL-2 is administered ranging from 600 000 to 720 000 
IU/kg/i.v. every 8 h for up to 14 consecutive doses over 5 d, fol-
lowed by a second treatment cycle after 6 to 9 d.2 Treatment of 
patients with advanced melanoma with HD IL-2 has demon-
strated a complete response (CR) rate of 6% and partial response 
rate of 10%. Among patients who reach CR, the response can 
be long-lasting. However, HD IL-2 is associated with significant 
acute toxicity (severe hypotension, pulmonary edema, systemic 
edema with significant weight gain and renal insufficiency, 
rash and fatigue).5 For this reason HD IL-2 requires the hos-
pitalization and is usually reserved for patients in a good per-
formance status. Alternative regimens have been investigated, 
but were unable to reach comparable response rates. The Society 
for Immunotherapy for Cancer (SITC) recommends HD IL-2 
as first-line treatment in patients with stage IV BRAF-wild type 
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immunotherapy is a cornerstone in the treatment of 
melanoma, and is intended to modulate the host immunity 
against the tumor. immunotherapy can be used in an adjuvant 
setting, after complete surgical excision in patients with a 
high risk of disease relapse and as a treatment in advanced 
(unresectable or metastatic) stages. Development of novel 
therapeutic approaches and the optimization of existing 
therapies hold a great promise in the field of melanoma 
therapy research. Different clinical trials are ongoing, and 
immunotherapy is showing the ability to confirm durable 
clinical benefits in selected groups of melanoma patients. 
The aim of this review is to summarize different types of 
immunotherapy agents, as well as to discuss different 
strategies, complementary regimens, and possible biomarkers 
of response to the treatment.
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melanoma who have a good performance status and no evidence 
of central nervous system disease.6 The genetic background of 
melanoma might also affect response rates for IL-2 treatment. 
A recent report7 suggests that neuroblastoma rat sarcoma viral 
oncogene (NRAS) mutations might predict a better response to 
IL-2 treatment.
Intralesional IL-2 for in-transit lesions
Surgical resection is the preferred therapeutic approach for 
in-transit metastases. However, when surgical excision cannot 
be pursued, another possible option is the intralesional injection 
of therapeutics. Injecting IL-2 into a metastatic lesion allows for 
very high intralesional concentrations without systemic toxicity. 
Several small series have reported promising clinical responses 
in treated lesions.8-11 Boyd et al. injected 10 million IU of IL-2 
in each lesion twice a week in a total of 39 patients and reported 
complete and partial responses in 51% and 31%, respectively.8 
Radny et al. used single doses from 0.6 to 6 million IU, depend-
ing on lesion size and injected 2–3 times weekly in a total of 24 
patients. They reported complete and partial responses in 63% 
and 21%, respectively.10 A systemic effect of this treatment was 
suggested, with a higher five-year survival in patients with a com-
plete response compared with patients with a partial response 
(80% vs 50%).8 To achieve increased local expression of the 
cytokine over a prolonged period of time, plasmid DNA (pDNA) 
Figure 1. Methods in cancer immunotherapy.
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expression vectors, which deliver the IL-2 gene into tumor cells, 
are used.12 The combination of vector delivery via intralesional 
injection followed by electroporation to facilitate cellular uptake 
of pDNA is an area of active research.13
Several other immunomodulatory gene therapy trials have 
been conducted; still the most promising results are achieved 
with administration of pDNA encoding IL-12 along with electro-
poration. This treatment has also induced responses in untreated 
lesions, suggesting an induction of systemic response.14
Interferon-α
Interferons are proteins secreted in order to communicate and 
trigger immune responses to eradicate pathogens and tumor cells. 
Interferon-α (IFN-α) directly inhibits the proliferation of tumor 
cells and increases MHC class I expression, enhancing antigen 
recognition. Moreover, IFN-α represses oncogene and induces 
tumor suppressor genes expression, in conjunction with antian-
giogenic effects.15 IFN-α is known to regulate the immune sys-
tem directly or indirectly by the induction of chemokines secre-
tion. In particular, the JAK-STAT pathway plays a critical role in 
the signaling events induced by IFN, this pathway activates tran-
scription factors STAT, and the activated STAT translocate to 
the nucleus followed by binding to IFN-stimulated response ele-
ments and modulating transcription of IFN-stimulated genes.16 
For example, STAT1 has been proved to be fundamental for the 
activation of NK cells in response to IFN in murine models.17 
While STAT1 enhances innate and adaptive immunity, STAT3 
appears to play opposite role in tumorigenesis, promoting sur-
vival, proliferation, motility, and immune tolerance. Studies in 
STAT-deficient cells have revealed the existence of reciprocal 
STAT1:STAT3 regulatory mechanisms, and their relative abun-
dance can be implicated in the biological effects in response to 
IFN activating stimuli.18
IFN in adjuvant treatment
Various systemic therapies have been examined for patients 
with stage II or III melanoma and a high risk of systemic recur-
rence after surgery excision. The immunotherapeutics approved 
by the FDA for the adjuvant treatment of melanoma are inter-
feron α-2b and peginterferon α-2b. The rationale for the use of 
the pegylated form is to reduce its rate of absorption following 
subcutaneous injection, to reduce renal and cellular clearance, 
and to decrease the immunogenicity of the protein. All of these 
effects tend to enhance the half-life of the pegylated protein. 
On the other hand, pegylation may interfere with the ability of 
a protein to bind to its receptor, thereby decreasing its biologic 
effect. Thus, the true biologic effect of the pegylated protein is 
determined by the balance of these competing properties of the 
interferon increases.19
Stage III melanoma with macroscopic nodal disease (N1b 
and N2–N3) is generally considered separately from that with 
microscopically involved lymph nodes (N1a). The SITC sug-
gests one year of interferon α-2b treatment or enrollment in 
specific clinical trials, for patients with macroscopic lymph node 
involvement.6 On the other hand, in the case of N1a disease, a 
1-y course of interferon α-2b, but also no further treatment, or 
shorter courses of interferon α-2b are suggested. Pegylated inter-
feron α-2b was recommended by a minority of panel members 
in N1a melanoma with ulcerated primary tumors or for patients 
unwilling or unable to tolerate the standard regimen of interferon 
α-2b treatment.6 Patients with stage II melanoma are considered 
at high-risk of recurrence if the primary lesion is ulcerated, larger 
than 4 mm in diameter, or has mitotic rate ≥1 per mm2. Special-
ists remain divided between recommending interferon α-2b and 
active surveillance.6 A recent randomized study showed a better 
overall survival in patients treated with a 1-y course of interferon 
α-2b (20 MIU/m2 intravenously daily 5 d per week for 4 wk, 
followed by IFN-α-2b 10 MIU/m2 administered subcutane-
ously three times per week for 48 wk) compared with a shorter 
course (20 MIU/m2 intravenously daily 5 d per week for 4 wk) 
in patients from stage IIB to stage IIIC.20 However, most of the 
patients included had a stage IIIB or IIIC at study entry suggest-
ing once more that 1 y of therapy offers the most benefit to those 
with macroscopic nodal metastasis and a higher risk of relapse.
Biochemotherapy
In the treatment of metastatic melanoma, the combination of 
chemotherapy with immunotherapy, biochemotherapy (BCT), 
has been explored in multiple trials. The most used regimen 
utilizes cisplatin, vinblastine, and dacarbazine with IL-2 and 
interferon-α-2b. This combination was designed to enhance 
immune recognition and effector cell activity triggered by IL-2 
during antigen release after tumor cell disruption and apoptosis 
Figure 2. Drugs FDA-approved for the treatment of melanoma with approval date.
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induced by cytotoxic chemotherapy. Two systemic reviews showed 
a higher overall response rate with this regimen compared with 
chemotherapy, but no significant survival advantage.21,22 A ran-
domized phase III trial compared BTC to interferon-α-2b as 
adjuvant therapy in 138 patients with stage 3 melanoma and high 
risk for recurrence, but didn’t detect significant differences in 
overall survival.23 Another randomized phase III trial compared 
BTC to interferon-α-2b as adjuvant therapy in 432 patients with 
stage III melanoma and found that BTC conferred a statistically 
significant improvement in relapse free survival compared with 
interferon; but no discernable difference in overall survival with 
also an higher occurrence of grade IV toxicity.24
Active Immunization
Vaccines
The aim of tumor vaccination is to induce immune recog-
nition with subsequent specific tumor cell eradication. Multiple 
approaches have been examined, the simplest strategy has been 
to administer defined tumor-associated antigens as whole pro-
teins or peptide fragments. Most protein- or peptide-based vac-
cines have lacked significant immunogenicity and were unable 
to induce a robust immune response in monotherapy. Therefore, 
the combination of peptide and/or protein vaccines with nonspe-
cific immunologic adjuvants, such as granulocyte-macrophage 
colony-stimulating factor (GM-CSF) or HD IL-2, has been 
investigated. These studies have not demonstrated a consistent 
benefit in overall survival to date.25 In an effort to induce a more 
specific tumor response, the administration of customized vac-
cines, derived from whole cells or cell lysates of patient’s tumor 
have been tested. However, these have also not shown any clinical 
benefit in randomized controlled trials. Other approaches that 
have been evaluated include recombinant vectors, which encode 
either an entire gene or the antigenic epitope,26 and dendritic cells 
pulsed with tumor cell RNA, DNA, or cell lysate.27
Adoptive Immunotherapy
The adoptive cell therapy (ACT) approach utilizes ex vivo cul-
tured autologous lymphocytes. These lymphocytes can be derived 
from resected metastasis or from peripheral blood. The optimi-
zation of the host environment prior to cell transfer appears to 
be very important for the success of this procedure: high dose 
chemotherapy is needed to induce lymphodepletion to eliminate 
immune regulatory elements (both cellular and humoral) that 
could affect homing and activity of transferred cells.28 Recent 
advances in ACT involve the use of autologous engineered T cells 
that express T-cell receptors specific for various tumor-associated 
antigens (such as MART-1-TCG genes), or that secrete specific 
cytokines.
ACT protocols are currently implemented in patients who 
failed prior systemic treatment for metastatic melanoma. The 
most common sites to harvest tumor-infiltrating lymphocytes 
(TILs) are soft tissue and lung metastases. Recently, several 
groups published results of phase II clinical trials testing TIL-
based ACT.29-32 The lymphodepleting regimen and the TIL 
production protocols varied in the different studies. The high-
est objective response rate (72%) was reported with the use of 
myeloablative pre-conditioning; whereas the use of CD8+ T cell-
enriched TILs in a non-myeloablative setting was associated 
with the lower response rates (20%). Interestingly, 19 out of 
20 patients in one study33 and all 5 patients in another study,34 
who completely responded to TIL-based ACT, have no evidence 
of disease after more than 3 and 2 y, respectively. This shows 
the great potential of ACT regimens in patients with advanced 
melanoma stages.
However, the toxicity of preparative chemotherapy mandates 
to investigate factors that predict treatment success. Combin-
ing ACT with other therapy approaches, such as ipilimumab 
or v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) 
inhibitors, as well as exploring synergistic effects of cytokines, 
such as IL15, are future directions, and clinical trials are under-
way (NCT01701674 and NCT01659151).35
Immune Checkpoints and Immune Modulator 
Molecules
The antitumor T-cell activity depends on the dendritic cell 
maturation stimulus received from the tumor, and on the suc-
cessful interaction of T-cell co-stimulatory molecules with sur-
face receptors on dendritic cells (Fig. 3). New immunotherapies 
target critical regulatory elements of the interaction between 
T cells, dendritic cells, and tumor cells. These include anti-
CTLA-4 monoclonal antibodies such as ipilimumab, toll-like 
receptor (TLR) agonists, CD40 agonists, anti-PD-1 or PDL-1 
antibodies, and others.
Anti-CTLA-4
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a receptor 
that interacts with CD80 (B7-1) and CD86 (B7-2) and downreg-
ulates T-cell response.36 CD28, although with less affinity than 
CTLA-4, usually binds to B7-1 and B7-2 leading to T cell activa-
tion. CTLA-4 receptors are highly expressed on tumor cell lines 
and inhibit T-cell responses and “mask” tumors from inducing 
a host immune response.37 The excessive CTLA-4 expression on 
tumor cells represents just one mechanism by which tumors are 
able to actively suppress and evade T-cell activity. Ipilimumab 
and tremelimumab (CP-675206) are monoclonal antibodies 
that block CTLA-4 and allow CD28 to bind to B7-1 receptors, 
which leads to IL-2 secretion, cytotoxic T-cell activation and 
proliferation.
Anti-CTLA-4 antibodies in metastatic melanoma
Clinical studies confirm that the CTLA-4 inhibitor ipilim-
umab can induce durable responses and improve overall survival 
in patients with advanced melanoma. A phase II study compar-
ing different dose regimens (0.3, 3, or 10 mg/kg IV every 3 wk) 
established that the best response was obtained with 10 mg/kg. 
However, at this dose, a significant increase in immune-related 
adverse effects (irAEs) was observed.38 In the first phase III trial, 
ipilimumab +/- glycoprotein 100 peptide (gp100) vaccine was 
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compared with gp100 vaccine monotherapy in patients with 
unresectable stage III or stage IV melanoma. Ipilimumab in 
monotherapy improved overall survival (OS) compared with 
gp100 vaccine monotherapy (10.1 mo vs. 6.4 mo). However, more 
irAEs were noticed with ipilimumab treatment. The combina-
tion of ipilimumab and gp100 did not improve OS as compared 
with ipilimumab alone.39 In another randomized phase III trial 
ipilimumab (10 mg/kg) combined with dacarbazine (850 mg/
mq) demonstrated a modest but statistically significant improve-
ment in OS compared with dacarbazine (850 mg/mq) plus pla-
cebo (11.2 mo vs. 9.1 mo). A higher incidence of total adverse 
events was recorded in the ipilimumab–dacarbazine group com-
pared with dacarbazine–placebo including elevation of alanine 
aminotransferase levels (in 29.1% of patients vs. 4.4%), elevation 
of aspartate aminotransferase levels (26.7% vs. 3.2%), diarrhea 
(32.8% vs. 15.9%), pruritus (29.6% vs. 8.8%), and rash (24.7% 
vs. 6.8%). Grade 3 or 4 adverse events occurred in 56.3% of 
patients treated with ipilimumab plus dacarbazine, as compared 
with 27.5% treated with dacarbazine and placebo (P < 0.001).40
Subsequently, ipilimumab was approved by the FDA in 2011 
for the treatment of unresectable or metastatic melanoma. Simi-
lar to other types of immunotherapy, ipilimumab demonstrates 
durable responses in a small subset of patients. Prieto et al. reported 
on 177 patients treated with ipilimumab in three different trials. 
56 patients received ipilimumab with gp100 peptides, 36 patients 
received ipilimumab with interleukin-2, and 85 patients received 
ipilimumab with intrapatient dose-escalation and were random-
ized to receive gp100 peptides. Out of these 177 patients, 9% 
experienced a complete response and all but one were durable 
during follow-up ranging from 54 to 99 mo. Responses were 
most frequently observed in patients who received a combination 
of HD-IL2 (720 000 IU/kg) and ipilimumab.41
First results with tremelimumab showed promising activity 
in phase I and phase II studies. Although, a subsequent phase 
III randomized trial comparing tremelimumab to chemotherapy 
(dacarbazine or temozolamide) in 655 patients with advanced 
melanoma revealed a not significant prolonged overall survival 
among patients treated with tremelimumab (11.8 mo with treme-
limumab vs. 10.7 mo with chemotherapy, P = 0.73).42 The fail-
ure of tremelimumab to improve outcome may be attributed to 
restrictive inclusion criteria of the study: patients with elevated 
LDH >2× upper limit of normal, a known negative prognostic 
indicator, were excluded from the control cohort, making the 
study populations unbalanced in terms of baseline prognos-
tic factors. This restriction was not present in the ipilimumab 
phase III trial.43
Anti-CTLA-4 antibody in adjuvant therapy
In a phase II trial, 75 patients with resected stage IIIC/IV 
melanoma were treated with ipilimumab to assess the safety and 
feasibility of this drug in an adjuvant setting.44 Improved out-
comes in terms of relapse-free survival and overall survival were 
reported compared with historical data; irAEs were generally 
reversible and appeared to be associated with improved relapse-
free survival.44 The European Organisation for Research and 
Treatment of Cancer (EORTC) melanoma group is conducting a 
phase III trial (EORTC 18071) where resected high-risk patients 
are randomized to ipilimumab treatment (dose 10 mg/kg every 3 
wk for 4 cycles, then every 12 wk for a total of 3 y treatment) or to 
placebo in order to determine whether adjuvant ipilimumab can 
prevent disease recurrence. Recruiting has been completed and 
the results are pending.35 In addition, a cooperative group trial 
is currently open to compare adjuvant ipilimumab to high-dose 
interferon α-2b in treating patients with high-risk stage III or 
stage IV melanoma (ECOG 1609).35 Given the minimal impact 
Figure 3. Dendritic cell and T cell interaction.
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of interferon in reducing disease recurrence, this study could pro-
vide additional evidence if immunotherapies have the potential 
to positively influence the immune system to eradicate minimal 
to microscopic residual disease resulting in prolonged OS.
Anti-PD-1 and PDL-1
Programmed death-1 (PD-1) receptor, also known as CD279, 
is a protein receptor that is inducibly expressed on CD4+ T cells, 
CD8+ T cells, natural killer T cells, and B cells. PD-1, interacting 
with programmed death ligand 1 (PDL-1) and PDL-2 negatively 
regulates immune responses.45-47 PD-1 expression usually occurs 
on T cells during long-term antigen expression and induces T-cell 
exhaustion. The interaction between tumor cells expressing 
PD-L1 and T cells expressing PD-1 prevents an effective immune 
response by inactivating T-cells (Fig. 4).
Monoclonal antibodies such as BMS-936558 (nivolumab) 
and MK-3475 block this immune suppressive interaction of PD-1 
and PDL-1. Nivolumab is a human monoclonal antibody target-
ing PD-1. A phase I study was conducted to test the efficacy and 
safety of a range of doses of nivolumab in patients with different 
cancers including 104 melanoma patients. The recommended 
phase II dose determined for nivolumab was 3 mg/kg IV every 
2 wk, and the incidence of irAEs, especially grade 3–4, was lower 
for patients taking nivolumab compared with the historical data 
in ipilimumab-treated patients (14% vs 25.2%). Among patients 
with melanoma treated at the recommended phase II dose of 
3 mg/kg, a response was noted in 7 out of 17 patients (41%).48 
Therefore, PD interference seems to display higher response rates 
and a beneficial side effects profile compared with CTLA-4 inhi-
bition. A clinical trial is currently recruiting patients in order to 
directly compare efficacy and safety of nivolumab and ipilim-
umab (NCT01844505).35
More recently, a study that combined nivolumab and ipili-
mumab was completed in patients with advanced melanoma.49 
The concurrent administration of the two drugs every 3 wk, 
for 4 doses, was compared with a sequenced regimen where 
patients previously treated with ipilimumab received nivolumab 
every 2 wk for up to 48 doses. A higher objective-response rate 
was observed with the concurrent treatment regimen (40% vs 
20%). However, grade 3 or 4 side effects occurred in 53% of 
the patients in the concurrent regimen and in 18% of patients in 
the sequenced-regimen group. The recommended phase II dos-
age for this regimen was nivolumab 1 mg/kg with ipilimumab 3 
mg/kg.49
A second antibody targeting PD-1, MK-3475, also showed 
promising results with response rates as high as 52%. Among 
the 57 patients treated with 10 mg/kg IV every 2 wk, 91% expe-
rienced irAE but only 23% were grade ≥3.50 Two more trials 
have recently been launched to examine the effects of MK-3475 
compared with chemotherapy (NCT01704287) and MK-3475 
compared with ipilimumab (NCT01866319).35 Preliminary data 
from trials with anti-PDL1 drugs (BMS-936559, MPDL3280A) 
do not seem to as promising as MK-3475 or nivolumab.51,52
Other modulators of immune regulatory checkpoints
CD40 agonist
CD40 is a co-stimulatory molecule expressed on dendritic 
cells, B cells, and monocytes (Fig. 3). Its ligand, CD40L, is 
expressed on CD4+ T cells. The interaction of CD40–CD40L 
triggers T-cell activation. CD-870 873 is a monoclonal anti-
body targeting CD40. In a phase I study, the administration 
of CD-870 873 was associated with the induction of melanoma 
antigen-specific T cells, which is believed to be the mechanism 
of action leading to partial responses which were observed in 
Figure 4. T cell and cancer cell interaction.
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27% of patients with metastatic melanoma. The most common 
adverse event was cytokine release syndrome (grade 1 to 2) which 
included chills, rigors, and fever.53 Preclinical data suggest a syn-
ergy between chemotherapy and CD40 agonists.54 In a phase I 
32 patients affected by advanced solid tumors were treated with 
a combination of CP-870 893, paclitaxel and carboplatin. Out of 
them, 25 patients were affected by metastatic melanoma. Six of 
the 30 evaluable patients (20%) had a partial response and half 
of them were melanoma patients.55 An ongoing trial is recruiting 
patients with stage IV melanoma in order to assess the most effec-
tive dose of CP-870 893 in combination with tremelimumab and 
the related side effects (NCT01103635).35
CD137 agonist
CD137 is an inducible T-lymphocyte surface molecule of the 
tumor necrosis factor (TNF) receptor superfamily. Its ligand, 
CD137L, can be expressed by most immune and many non-
immune cells as a transmembrane protein (Fig. 3). CD137 sig-
naling enhances T-lymphocyte proliferation and T-helper-1 cyto-
kine production, protecting CD8+ T-lymphocytes from apop-
tosis. A phase I–II study of BMS663513, a human monoclonal 
antibody agonist of CD137, showed clinical activity with partial 
remission and stable disease in a subset of patients. However, a 
high incidence of grade 4 hepatitis was reported and the study 
had to be discontinued.56
Agonistic antibodies targeting OX40
OX40 and its ligand, OX40L (Fig. 3), are key TNF members 
that augment T-cell expansion, cytokine production, and cell sur-
vival. OX40 is a co-stimulatory molecule expressed transiently on 
the surface of T cells. Agonistic antibodies targeting OX40 have 
been shown to have antitumor activity.57 A phase I with a proof-
of-concept phase II trial was initiated to study in patients with 
unresectable or metastatic melanoma the combination of OX40 
and ipilimumab, but the phase II trial to assess the immune 
system response to treatment with OX40 antibodies in mono-
therapy was withdrawn prior to enrollment due to changes in 
the development plan for the OX40 antibody (NCT01416844).35
Anti-LAG-3 antibody
Lymphocyte activation gene-3 (LAG-3) is a transmembrane 
protein that binds MHC class II molecules, enhances regulatory 
T-cell activity, and negatively regulates cellular proliferation, 
activation, and homeostasis of T cells (Fig. 3).58 Further studies 
revealed a synergy between PD-1 and LAG-3 pathways to induce 
tolerance to self and tumor antigens.59 Therefore, the dual block-
ade of these molecules might be a promising combinatorial strat-
egy for cancer treatment. Moreover, melanoma cells often express 
MHC class II molecules, and the LAG-3-MHC II interaction 
protects tumor cells from apoptosis.59 Targeting LAG-3 could 
serve as a bidirectional way to prevent tumor immune escape; 
however, the effects on autoimmunity are yet to be explored. A 
clinical trial to assess safety of anti-LAG-3 with or without anti-
PD-1 in patients with solid tumors is currently recruiting patients 
(NCT01968109).35
Anti-TIM-3 antibody
T-cell immunoglobulin mucin-3 (TIM-3) is another inhibi-
tory receptor expressed on a subset of tumor reactive T cells. 
Blockage of TIM-3 has been shown to improve the function 
of anti-tumor T cells in different experimental models (Fig. 3). 
These findings provide the rationale for the clinical develop-
ment of agents targeting these molecules. Interestingly, TIM-3 
is frequently co-expressed with PD-1, and TIM-3/PD-1 express-
ing cells represented the majority of tumor-infiltrating T cells.60 
Combined targeting of the TIM-3 and PD-1 pathway will be an 
interesting future treatment approach, but to date clinical trials 
are not on going yet.
Biomarkers for Immunotherapy
Several immunomodulatory strategies and combinatory 
approaches involving target inhibitors, immunotherapy, chemo-
therapy, surgery, and radiation have showed promising results in 
several clinical trials. However, a significant fraction of patients 
does not respond to treatment. The development of robust selec-
tion criteria and discovery of biomarkers predicting a response to 
certain treatment strategies is needed to improve response rates, 
disease-free survival, and OS. Selecting for the right patients will 
limit the risk of potentially severe irAEs to patients that are most 
likely to respond, thus greatly improving patient care.
Interleukin-2
Patients with limited subcutaneous and/or cutaneous metas-
tases respond significantly better to IL-2 treatment than patients 
with other sites of disease.61 Although high levels of serum 
VEGF, fibronectin,62 and C-reactive protein63 are not established 
as predictive biomarkers, they have been correlated with a lack of 
clinical response. A recent report7 is suggestive of higher clinical 
responses to HD IL-2 in patients with NRAS mutations (47% 
responses in NRAS mutant melanoma patients vs 19% in wild 
type, P = 0.04). To date, the majority of predictors for a response 
to IL-2 treatment have been post-treatment variables, such as 
magnitude of rebound lymphocytosis, treatment-induced throm-
bocytopenia, development of autoimmune thyroiditis and vitil-
igo and decrease in absolute peripheral T regulatory cell count.64
Adoptive cell therapy
Retrospective analyses have revealed several factors associated 
with response in ACT trials. The persistence of transfused cells in 
circulation after 1 mo,65-67 the telomere length of infused cells68 
and the elevation of plasmatic levels of cytokines (such as IL-7 
and IL-1569) were found to correlate with the response to ACT.
Immune-checkpoint regulatory molecules
Several large studies have reported increased efficacy of anti-
CTLA-4 in patients who experience irAEs with responses in 26% 
of patients with irAE, compared with 2% in patients without.70-72 
There was also a “severity response effect” with slightly better 
response rates for patient grade 3–4 adverse reactions compared 
with patients with grade 1–2.70 Several recent studies have shown 
that an absolute lymphocyte count (ALC) > 1000/μL with an 
increase in the ALC after 2 ipilimumab treatments correlates 
with clinical benefit (complete and partial response or stable 
disease 24 wk after beginning of the treatment) and OS.72,73 In 
addition, increased expression of inducible costimulator molecule 
(ICOS) on T cells and a neutrophil/lymphocytes ratio below the 
median may represent an early marker of response.3
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Other approaches trying to predict the response to immuno-
therapy focus on the tumor microenvironment. A recent study 
observed improved prognosis among patients with metastatic 
melanoma when a 12-chemokine gene expression signature 
(CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, 
CXCL9, CXCL10, CXCL11, and CXCL13) was detected in the 
tumor microenvironment. This chemokine expression profile 
can be used to predict the likelihood that patients will respond 
favorably to immunotherapy.74 A new concept known as immu-
noprofiling uses the genetically determined or tumor-induced 
immune response as a predictive factor for the response to immu-
notherapy.75 Immunohistochemical analysis of pre- and post-
treatment tumor biopsies from patients treated with ipilimumab 
has shown, that the tumor microenvironment may predict clini-
cal activity. Baseline high expression of FoxP3 and indoleamine 
2,3-dioxygenase (IDO), and a high count of tumor-infiltrating 
lymphocytes at baseline are related to a higher clinical activity 
of ipilimumab.76 These biomarkers could help to develop an 
immunoprofiling panel to select patients that are more likely to 
respond to anti-CTLA-4 therapy.75
Different studies suggest a relationship between PD-L1 
expression on tumor cells and objective response to both anti-
PD-1 antibodies48,77 and anti-PD-L1 antibodies.52 This also sug-
gests that other immune checkpoint regulatory molecules such as 
anti-OX40, anti-TIM3 among others, may be useful to predict 
efficacy of therapeutics.
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